Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Foresite Capital

Investor type Private Equity Firm
Founders Jim Tananbaum


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 141
Average round size
The average size of a deal this fund participated in
Portfolio companies 95
Rounds per year 12.82
Lead investments 24
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 41
Key employees 11
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Medical

In 2011 was created Foresite Capital, which is appeared as VC. The main department of described VC is located in the San Francisco. The company was established in North America in United States.

The current fund was established by Jim Tananbaum. The overall number of key employees were 11.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Foresite Capital, startups are often financed by Venrock, Third Rock Ventures, Paladin Capital Group. The meaningful sponsors for the fund in investment in the same round are Cormorant Asset Management, ARCH Venture Partners, Paladin Capital Group. In the next rounds fund is usually obtained by Paladin Capital Group, Merieux Developpement, EcoR1 Capital.

The higher amount of exits for fund were in 2015. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 7-12 investment rounds annually. The real fund results show that this VC is 9 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 50 - 100 millions dollars. The typical startup value when the investment from Foresite Capital is more than 1 billion dollars. Opposing the other organizations, this Foresite Capital works on 12 percentage points more the average amount of lead investments.

Among the various public portfolio startups of the fund, we may underline AveXis, Intarcia Therapeutics, Audentes Therapeutics Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Health Care, Genetics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Foresite Capital:
Typical Co-investors
Foresite Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Foresite Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

FOLX Health

Health Care
$30M12 Oct 2022 Boston, Massachusetts, United States

Nested Therapeutics

Health Care
Health Diagnostics
Medical Device
$90M06 Oct 2022 Cambridge, Massachusetts, United States


Life Science
$23M21 Jun 2022 Palo Alto, California, United States

Remix Therapeutics

Health Care
$70M17 May 2022 Cambridge, Massachusetts, United States

Kriya Therapeutics

Life Science
$270M16 May 2022 Palo Alto, California, United States


Cloud Computing
$200M08 Mar 2022 Mountain View, California, United States

TenSixteen Bio

Health Care
$40M27 Jan 2022 San Francisco, California, United States


Life Science
$111M20 Jan 2022 California, United States

Maze Therapeutics

$190M10 Jan 2022 Redwood City, California, United States
XinThera Closes $50M Series B Financing

– XinThera, a company focused on building a small molecule oncology and immunology pipeline, announced that the company has raised $50M in Series B financing.
– New investor Orbimed Advisors, LLC joined existing investors Foresite Capital and TTM Capital, bringing the total financing raised to $80M.
– The funds will be used to support the firm’s recruiting efforts and build its product pipeline.
– XinThera brings together a founder and investors that previously worked together to incubate, fund and launch Kinnate Biopharma, a company that progressed from idea to IPO in less than three years.
– Stephen Kaldor, Ph.D., co-founder and chairman of XinThera has more than 25 years of experience in creating meaningful medicines and shareholder value.

Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies

– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Foresite Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: